Abstract 18851: Trends in Statin Utilization and Expenditures Among US Adult Population: Insight From Medical Expenditure Panel Survey (2002-2013)
Objectives: Recent AHA/ACC guideline updates strongly emphasize the role of statins as pharmaceutical agents of choice for atherosclerotic cardiovascular (ASCVD) risk management. In this study we quantify annual trends in utilization, total expenditure, and patient cost shares with statin use in a representative US adult population between 2002 and 2013.
Methods: We obtained 2002-2013 data from publicly available Medical Expenditure Panel Survey (MEPS) database. Full-year consolidated, medical conditions and prescribed medicines file files were used to generate estimates of statin utilization, expenditure and payment share. Costs were adjusted to 2013 USD using Gross Domestic Product Index.
Results: As shown in table, among the 121.5 million US adults aged 40 years and above in 2002-2003, 17.9% reported statin use (134 million prescriptions), increasing to 27.2% in 2012-2013 (217 million prescriptions). Any statin use among US adults with ASCVD was 49.4% (10.3% high intensity) and 55.8% (16.1% high intensity) in the respective time period. Atorvastatin (52%) was most commonly used statin in 2002-2003 vs. simvastatin (42%) in 2012-20013. The proportion of generic statins substantially increased from 8.4 to 82.2% over the 12-year period. The GDP adjusted cost for statins was $17.2 billion in 2002-2003 vs. annual cost $ 15.5 billion (51% cost accounted by branded statins) in 2012-2013. In the same time period, patient cost share for statins decreased from 40.1% ($ 6.9 billion) to 21.3% ($ 3.3 billion) dollars; the corresponding average annual out of pocket cost for patients were also substantially lowered ($280 vs. $94).
Conclusion: Among US adult population, statin use increased substantially in the last decade, though it remains suboptimal in high risk groups. While total expenditure and patient financial burden with statins are decreasing, even in the face of greatly expanded usage, further substitution of branded to generics can yield significant savings
Author Disclosures: J.A. Salami: None. H.J. Warraich: None. J. Valero-Elizondo: None. O. Ogunmoroti: None. S.S. Virani: None. R. Blankstein: None. M.J. Blaha: None. A. Khera: None. E.S. Spatz: None. R. Blumental: None. D. Lloyd-Jones: None. K. Nasir: None.
- © 2016 by American Heart Association, Inc.